ArticleFrontiers in immunology2025
Multi-omics analysis and metastasis risk factor prediction in N1b stage PTMC: insights into immune infiltration and therapeutic implications.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Risk factors associated with lymph node metastasis in cN0 papillary thyroid microcarcinoma.Frontiers in oncology · 2026Article
- Noninvasive immune-inflammatory profiling by ultrasound radiomics for preoperative prediction of central lymph node metastasis in papillary thyroid carcinoma.Frontiers in immunology · 2026Article
- An interpretable machine learning-based approach: development, validation, and clinical utility for distant metastasis prediction in PTC.Frontiers in endocrinology · 2026Article
- Development and validation of a novel hepato-metabolic-renal score nomogram for predicting disease-free survival in head and neck squamous cell carcinoma.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Papillary thyroid microcarcinoma (PTMC) with lateral neck lymph node involvement exhibits a deceptively indolent yet highly invasive phenotype, characterized by early dissemination and slow tumor growth. A comprehensive understanding of integrating multiomics landscapes, circulating immune profiles, and tumor immune microenvironment is essential for more accurate surveillance and tailored therapeutic strategies. Methods: Clinical profile and circulating immune-inflammatory markers from 638 PTMC patients were analyzed using multivariate and least absolute shrinkage and selection operator (LASSO) regression to recognize N1b-associated risk indicators. Eight supervised machine learning models were trained via 10-fold cross-validation to select the optimal classifier. Weighted gene coexpression network analysis (WGCNA) alongside machine learning identified metastasis-related gene modules from the integrated RNA-seq profile, leading to a multilayer perceptron gene classifier. Genomic profiling was employed to investigate mutations, copy number alterations, and methylation modifications in signature genes, followed by screening of antineoplastic drugs and docking simulations to explore their therapeutic potential. CIBERSORT, combined with immunohistochemistry, was used to investigate immune infiltration and functional changes in N1b-stage PTMC lesions. Results: Two clinical metastasis risk models were developed, with Model A based on the neutrophil-to-lymphocyte ratio (NLR) and Model B on lymphocyte and neutrophil counts, where Model A showed superior generalization (AUC = 0.852) and discriminative performance. NLR was an independent risk determinant for N1b-stage PTMC (OR = 2.12, p < 0.01). Transcriptomic profiling revealed a molecular signature ( Discussion: This study constructed a robust metastasis prediction nomogram for N1b-stage PTMC and identified metastasis-associated molecular drivers through integrative multiomics analysis. Comprehensive profiling of systemic and tumor-infiltrating immunity revealed key antitumor immune alterations. These findings establish a framework for early metastatic phenotype detection, potentially inspiring relevant immunotherapeutic hypotheses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.